<DOC>
	<DOC>NCT00900614</DOC>
	<brief_summary>The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.</brief_summary>
	<brief_title>Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Summary criteria for participant selection: Male or female â‰¥ 18 years of age. Any below mentioned advanced disease, which is not eligible for other therapies. The diagnosis should have been confirmed either histologically or cytologically: 1. Acute myeloid leukemia. 2. Acute lymphoid leukemia. 3. Chronic lymphocytic leukemia. 4. Chronic myeloid leukemia. 5. Chronic myelomonocytic leukemia. 6. Multiple myeloma. 7. Non Hodgkin's lymphoma. 8. Hodgkin's lymphoma. 9. Myelodysplastic syndrome. 10. Myelofibrosis. 11. Hormone refractory, metastatic prostate carcinoma.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Prostate carcinoma</keyword>
	<keyword>Hematologic cancer</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>